View Report Details Global Multiple Myeloma Market: Industry Analysis & Outlook ----------------------------------------(2016-2030)
View Report Details Executive Summary Multiple Myeloma is a form of blood cancer. Blood cancers, or hematologic cancers, affect the production and function of blood cells. Most of these cancers start in the bone marrow where blood is produced. In myeloma, unusually large numbers of abnormal plasma cells gather in bone marrow and stop it from producing an important part of your immune system. Multiple myeloma is a cancer formed by malignant plasma cells. Multiple myeloma is characterized with low blood counts, bone and calcium problems, infections, kidney problems and nervous system symptoms. Usually the age factor is considered as the most prominent factor in multiple myeloma cases. Multiple myeloma was considered to be a non-treatable disease but hopes have arrived with the approval of Darzalex which was a much awaited product and has shown positive results in the trials. Many other products are in the pipeline and will arrive after some time. Darzalex is an antibody with immense potential and was the first monoclonal antibody approved by the FDA for the treatment of heavily pretreated double reverted multiple myeloma. More experiments have started to check out Darzalex in combinations to find out its effectiveness in case of other problems too. The key factors which are anticipated to drive multiple myeloma market include increased penetration of cancer drugs, increase in ageing population, rising obese population and increase in healthcare expenditure. Some of the significant developments of this industry include upcoming new innovative products in the market, trend of combination therapies, and chance of new players. However, the challenge to be faced ahead is high price and legal regulations. This report offers a comprehensive analysis of the Global Multiple Myeloma market. Furthermore, market dynamics such as key trends and development; and challenges are analyzed in depth. On the contention front, the global market is reined by few major players namely Johnson & Johnson, Roche Holding, Sanofi and Novartis. The competitive landscape of the respective market, along with the company profiles of the leading players are also discussed in detail.
Increase in ageing population, rising obese population, and increase in healthcare expenditure will drive the global multiple myeloma market. Global Blood Cancer Market Forecast by Value (2015/2020) US$ Billion
As of 2015, the global blood cancer market was valued at US$..... billion which is estimated to increase to US$..... billion by 2020. The multiple myeloma market is expected to gain a market of US$..... million in 2016 which is estimated to increase to US$..... million by 2030. The global forefront treated patients number is estimated to be …… in 2016 which is projected to reach …… by 2030. In the US, it is expected that the number of forefront patients to be treated would be ……. in 2016 which is estimated to be ……. by 2030. 2020
US$ Million
Global Multiple Myeloma Market Forecast by Value (2016-2030)
T r e a te d F o r e fr o n t P a tie n ts
2015
Global Forefront Treated Patients Forecast (2016-2030)
2016
2016
2020
2025
2030
2020
2025
2030
R e v e r te d T r e a te d P a tie n ts
Launch of Monoclonal Antibodies, Trend of combination therapies, space for new players are the latest developments and trends. Global Reverted Treated Patients Forecast (2016-2030)
The global reverted treated patients are expected to reach ……… in 2016 which is estimated to increase to …….. by 2030. The total market for multiple myeloma in the US is valued at US$...... million and is estimated to increase to US$..... million by 2030.
2016
2020
2025
2030
US$ Million
The US Multiple Myeloma Market Forecast by Value (2016-2030)
R e v e r te d T r e a te d P a tie n ts
In the reverted segment, the number of treated patients is assessed to be ……. in 2016 which is expected to increase continuously to reach ……. by 2030
The US Reverted Treated Patients Forecast (2016-2030)
2016
2016
2020
2025
2030
2020
2025
2030
High price and legal regulations are the main challenges to the global multiple myeloma market. Europe Multiple Market Forecast by Value (2016-2030) US$ Million
In the US, it is expected that the number of forefront patients to be treated would be …….. in 2016 which is estimated to be …….. by 2030 The increased prevalence of multiple myeloma has led the estimations of the market to increase from US$..... million in 2016 to US$..... million by 2030. It is estimated that the multiple myeloma market will be valued at US$..... million by 2020 and is projected to increase to US$..... million by 2030. It is estimated that the Darzalex’s sales will be valued at US$..... million globally in 2016 which will increase to US$....... million by 2020. 2016
2020
2025
2030
ROW Multiple Market Forecast by Value (2020-2030)
US$ Million
US$ Million
Darzalex Global Sales Forecast by Value (2016-2020)
2016 2020
2025
2030
2017
2018
2019
2020
Contact Us: View Report Details These are abridged and sanitized sample pages from the comprehensive report on the “ Global Multiple Myeloma Market ”. To know more about this report or for any customized research requirement, please contact the following:
Koncept Analytics
Vikas Gupta BD Manager
CS-36, Second Floor, Ansal Plaza Vaishali, Ghaziabad, U.P. – 201010 T. +91-120-4130959 C: +91-9811715635 vikas@konceptanalytics.com
www.konceptanalytics.com